Skip to main content
. Author manuscript; available in PMC: 2023 Jul 11.
Published in final edited form as: Eur Respir J. 2021 Dec 31;59(1):2003337. doi: 10.1183/13993003.03337-2020

FIGURE 4.

FIGURE 4

Display of competing risks estimates including death, lung transplant, alive with pulmonary hypertension (PH) and alive off PH medications for the PPHNet Registry World Symposium on Pulmonary Hypertension (WSPH) a) Group 1 and b) Group 3 incident cohort. c) In comparison with Group 1 disease, longitudinal follow-up of patients within Group 3 demonstrates a pattern of greater rates of cessation of PH medications with lower mortality with time.